Mifeprex Labeling Change: “Routine” Response To Adverse Events, FDA Says
Executive Summary
FDA's decision to strengthen warnings on Danco's Mifeprex (mifepristone) is not a signal that the agency will move to pull the product off the market, Center for Drug Evaluation & Research Acting Director Steven Galson, MD, said Nov. 16